Aspen Neuroscience Secures $115 Million Series C to Advance Parkinson’s Cell Therapy; IPO Considered for 2026
Aspen Neuroscience closed a $115 million Series C financing round in November 2025, led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and Revelation Partners1247.
This funding will accelerate the clinical development of Aspen's lead autologous cell therapy candidate, ANPD001, targeting moderate to advanced Parkinson's disease124.
The investment is planned to support ongoing clinical trials, expand manufacturing capabilities for future commercial demand, and further Aspen’s pipeline of autologous iPSC-derived therapies for additional neurological conditions145.
Aspen has raised a total of $340 million to date, which includes an $8 million grant from the California Institute for Regenerative Medicine23.
Leadership noted this Series C round strengthens the company's commercial readiness, scaling operations for potential future market entry4.
Aspen is actively considering an initial public offering (IPO) in 2026 as a next step in its strategy to bring its cell therapy to market23.
Board Chairman Faheem Hasnain highlighted the company's innovation in product characterization, manufacturing automation, and positive clinical results as key factors in securing the investment4.
Aspen is positioned as a leader in developing personalized, disease-modifying therapies for Parkinson's and other neurodegenerative disorders45.
Sources:
1. https://aspenneuroscience.com/aspen-neuroscience-announces-115-million-series-c-financing-to-accelerate-personalized-cell-therapy-programs/
2. https://www.noahai.co/discover/article/13039
3. https://www.biopharmadive.com/news/aspen-neuroscience-stem-cell-therapy-parkinsons-series-c/806048/
4. https://www.morningstar.com/news/pr-newswire/20251120la29248/aspen-neuroscience-announces-115-million-series-c-financing-to-accelerate-personalized-cell-therapy-programs